Amendment to Schedule 13D Filing for CAMP4 THERAPEUTICS CORPORATION

This filing is an amendment to a previously submitted Schedule 13D. Enavate Sciences GP, LLC and Everest Aggregator, LP, collectively, now hold 3,127,360 shares of CAMP4 THERAPEUTICS CORPORATION common stock, representing 6.0% ownership. This is a new filing for these entities regarding this security. In the past sixty days, Everest LP has sold a total of 578,926 shares in various open market transactions. The weighted average sales price for these transactions ranged from $6.10 to $6.87 per share. The total number of shares outstanding as of November 3, 2025, was 46,881,134, with an additional 5,000,000 shares issued in a public offering on December 19, 2025. Enavate GP shares voting and investment authority over the shares held by Everest LP.